Differential benefits and outcomes of tirofiban vs abciximab for XXXX in current clinical practice.

@entity1 @entity1187 @entity407 @entity712 @entity64 @entity101 @entity1396 @entity6 @entity63 @entity1397 @entity6541 @entity117 @entity548 @entity1459 @entity453 @entity583 @entity204
Little comparative data exist for glycoprotein IIb/IIIa inhibitors in @entity1187 ( @entity1187 ). Two hundred twenty-eight @entity1 were studied: 114 received @entity6541 (TI) and 114 received abciximab (AB) for either @entity1459 ( @entity1459 ) or @entity583 ( @entity583 ). All @entity1 received @entity117 , heparin, and @entity1396 or @entity1397 . Baseline characteristics were similar between the 2 groups for admitting diagnosis ( @entity1459 vs @entity583 ), age, gender, ejection fraction, @entity6 , prior @entity453 , prior @entity583 ( @entity583 ), prior bypass surgery, @entity101 , @entity712 , @entity407 , @entity583 type (Q vs non-Q), or location. Drug administration time (mean) was 13 hours (AB) and 24 hours (TI). All AB was administered in the catheterization laboratory as compared to TI (34% in laboratory and 66% before laboratory). More AB @entity1 received angioplasty or stent (92% vs 80%, p = 0.008) while more TI @entity1 had CABG (10% vs 3%, p = 0.027). In-hospital complications including @entity204 , @entity583 , urgent revascularization, @entity64 or transient @entity63 attacks, and access site @entity548 were similar (p = NS). Multivariate predictors of events (odds ratios) were prior coronary artery bypass graft (2.3), @entity6 (1.7), and prior percutaneous transluminal coronary angioplasty (1.7), but not the agent used. Over a mean follow-up of 13 months, the individual endpoints of @entity204 , @entity583 , revascularization, or hospitalization were similar for both groups. The AB @entity1 had improved freedom from revascularization (100% vs 81%, p = 0.015) in an emergent setting and TI @entity1 had improved freedom from revascularization (93% vs 77%, p = 0.038) with elective procedures. Tirofiban and abciximab appear effective and safe when used for @entity1187 when recommended dosing and precautions are followed. Major adverse outcomes are rare and @entity548 complications uncommon.
